David Andrew Hoffman - 03 Jan 2023 Form 4 Insider Report for First Wave BioPharma, Inc. (ENTO)

Reporting relationship: Director
Issuer ticker: ENTO
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2023, 07:56:53 UTC
Prior SEC filing: 04 May 2022
Source filing: View source filing
Reporting owner signature: /s/ David Hoffman

Key filing fact

David Andrew Hoffman filed Form 4 for First Wave BioPharma, Inc. (ENTO) on 05 Jan 2023.

Key facts

This page summarizes David Andrew Hoffman's Form 4 filing for First Wave BioPharma, Inc. (ENTO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2023, 07:56.

Change

Previous filing in this sequence was filed on 04 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FWBI transaction

Common Stock

Award

Transaction value: $0
Shares: +84,745
Change %: +1405%
Price: $0.000000
Shares after: 90,778
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Footnote F2

Includes unvested RSUs.